HUP0302521A2 - Neurotrophic tacrolimus analogs, pharmaceutical compositions containing them and their use - Google Patents
Neurotrophic tacrolimus analogs, pharmaceutical compositions containing them and their useInfo
- Publication number
- HUP0302521A2 HUP0302521A2 HU0302521A HUP0302521A HUP0302521A2 HU P0302521 A2 HUP0302521 A2 HU P0302521A2 HU 0302521 A HU0302521 A HU 0302521A HU P0302521 A HUP0302521 A HU P0302521A HU P0302521 A2 HUP0302521 A2 HU P0302521A2
- Authority
- HU
- Hungary
- Prior art keywords
- neurotrophic
- pharmaceutical compositions
- compositions containing
- tacrolimus analogs
- tacrolimus
- Prior art date
Links
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 title abstract 2
- 230000000508 neurotrophic effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 239000003076 neurotropic agent Substances 0.000 abstract 1
- 230000002276 neurotropic effect Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Packages (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
A jelen találmány tárgyát magas szintű neurotrop hatású és kismértékben immunoszuppresszív hatással rendelkező (I) képletűtacrolimusszármazék képezi. Ezek a vegyületek neurotróphatóanyagokként kerülnek alkalmazásra, különösen az idegisérülés/rendellenesség megelőzésére vagy kezelésére. A találmánykiterjed a vegyületeket tartalmazó gyógyszerkészítményekre is. ÓThe subject of the present invention is a tacrolimus derivative of the formula (I) with a high neurotropic effect and a small immunosuppressive effect. These compounds are used as neurotropic agents, particularly for the prevention or treatment of nerve injury/disorder. The invention also extends to pharmaceutical preparations containing the compounds. HE
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25850000P | 2000-12-29 | 2000-12-29 | |
| PCT/US2001/050419 WO2002053159A1 (en) | 2000-12-29 | 2001-12-31 | Neurotrophic tacrolimus analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0302521A2 true HUP0302521A2 (en) | 2003-11-28 |
| HUP0302521A3 HUP0302521A3 (en) | 2007-03-28 |
Family
ID=22980816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0302521A HUP0302521A3 (en) | 2000-12-29 | 2001-12-31 | Neurotrophic tacrolimus analogs, pharmaceutical compositions containing them and their use |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1353671A4 (en) |
| JP (1) | JP2004527472A (en) |
| KR (2) | KR20070030331A (en) |
| CN (1) | CN1293877C (en) |
| AR (1) | AR035411A1 (en) |
| AU (1) | AU2002231277B2 (en) |
| BR (1) | BR0116762A (en) |
| CA (1) | CA2433384A1 (en) |
| CZ (1) | CZ20032060A3 (en) |
| HU (1) | HUP0302521A3 (en) |
| IL (1) | IL156664A0 (en) |
| MX (1) | MXPA03005941A (en) |
| NO (1) | NO20032913D0 (en) |
| NZ (1) | NZ527209A (en) |
| PL (1) | PL366301A1 (en) |
| RU (1) | RU2288716C2 (en) |
| WO (1) | WO2002053159A1 (en) |
| ZA (1) | ZA200305806B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
| CA2554045A1 (en) * | 2004-01-20 | 2005-07-28 | Astellas Pharma Inc. | Method for treating erectile dysfunction |
| EP1810675A1 (en) * | 2006-01-18 | 2007-07-25 | Institut Curie | Method for treating Huntington's disease by inhibiting dephosphorylation of huntingtin at S421 |
| JP2009102226A (en) * | 2006-02-14 | 2009-05-14 | Meiji Milk Prod Co Ltd | Therapeutic agent for spinal cord injury |
| JP5878015B2 (en) * | 2008-07-23 | 2016-03-08 | ノバルティス アーゲー | Sphingosine monophosphate receptor modulators and their use to treat muscle inflammation |
| JP2015511242A (en) * | 2012-02-23 | 2015-04-16 | インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラリシェルシェ メディカル） | Calcineurin inhibitors for use in the treatment of pathological vestibular disorders |
| GB201309375D0 (en) * | 2013-05-24 | 2013-07-10 | Chronos Therapeutics Ltd | Medical methods and compounds for medical use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2799208B2 (en) * | 1987-12-09 | 1998-09-17 | フアイソンズ・ピーエルシー | Macrocyclic compound |
| GR1001225B (en) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Novel macrocyclic compositions and new application method thereof |
| US5541193A (en) | 1991-09-05 | 1996-07-30 | Abbott Laboratories | Heterocycle-containing macrocyclic immunomodulators |
| GB9202196D0 (en) * | 1992-02-01 | 1992-03-18 | Fisons Plc | Method of treatment |
| GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
| GB9917158D0 (en) * | 1999-07-21 | 1999-09-22 | Fujisawa Pharmaceutical Co | New use |
-
2001
- 2001-12-27 AR ARP010106058A patent/AR035411A1/en unknown
- 2001-12-31 BR BR0116762-6A patent/BR0116762A/en not_active Application Discontinuation
- 2001-12-31 CA CA002433384A patent/CA2433384A1/en not_active Abandoned
- 2001-12-31 PL PL01366301A patent/PL366301A1/en not_active Application Discontinuation
- 2001-12-31 HU HU0302521A patent/HUP0302521A3/en unknown
- 2001-12-31 IL IL15666401A patent/IL156664A0/en unknown
- 2001-12-31 RU RU2003123493/15A patent/RU2288716C2/en not_active IP Right Cessation
- 2001-12-31 JP JP2002554109A patent/JP2004527472A/en not_active Ceased
- 2001-12-31 CN CNB018228860A patent/CN1293877C/en not_active Expired - Fee Related
- 2001-12-31 AU AU2002231277A patent/AU2002231277B2/en not_active Ceased
- 2001-12-31 CZ CZ20032060A patent/CZ20032060A3/en unknown
- 2001-12-31 KR KR1020077003889A patent/KR20070030331A/en not_active Application Discontinuation
- 2001-12-31 NZ NZ527209A patent/NZ527209A/en unknown
- 2001-12-31 EP EP01991558A patent/EP1353671A4/en not_active Withdrawn
- 2001-12-31 MX MXPA03005941A patent/MXPA03005941A/en active IP Right Grant
- 2001-12-31 WO PCT/US2001/050419 patent/WO2002053159A1/en active IP Right Grant
- 2001-12-31 KR KR1020037008787A patent/KR100794204B1/en not_active IP Right Cessation
-
2003
- 2003-06-24 NO NO20032913A patent/NO20032913D0/en not_active Application Discontinuation
- 2003-07-28 ZA ZA2003/05806A patent/ZA200305806B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002231277B2 (en) | 2006-11-30 |
| IL156664A0 (en) | 2004-01-04 |
| ZA200305806B (en) | 2005-01-26 |
| EP1353671A4 (en) | 2004-07-14 |
| CN1538843A (en) | 2004-10-20 |
| KR20040007431A (en) | 2004-01-24 |
| CA2433384A1 (en) | 2002-07-11 |
| EP1353671A1 (en) | 2003-10-22 |
| JP2004527472A (en) | 2004-09-09 |
| MXPA03005941A (en) | 2005-02-14 |
| NO20032913D0 (en) | 2003-06-24 |
| NZ527209A (en) | 2005-09-30 |
| PL366301A1 (en) | 2005-01-24 |
| KR100794204B1 (en) | 2008-01-14 |
| WO2002053159A1 (en) | 2002-07-11 |
| AR035411A1 (en) | 2004-05-26 |
| CZ20032060A3 (en) | 2004-01-14 |
| CN1293877C (en) | 2007-01-10 |
| BR0116762A (en) | 2004-08-10 |
| RU2288716C2 (en) | 2006-12-10 |
| HUP0302521A3 (en) | 2007-03-28 |
| KR20070030331A (en) | 2007-03-15 |
| RU2003123493A (en) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00513B (en) | Azabicycloalkanes as ccr5 modulators | |
| AP2004003069A0 (en) | 3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof. | |
| HUP0202570A1 (en) | Compositions and therapeutic methods involving isoflavones and analogues thereof | |
| EA200701296A1 (en) | 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines | |
| EP1673078A4 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| EP1689713A4 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer s disease | |
| YU40701A (en) | Piperidines as ccr5 modulators | |
| HUP0302980A2 (en) | Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moeties as inhibitors of protein junkinases and pharmaceutical compositions containing them | |
| HRP20040317A2 (en) | 1,8-naphthyridine derivatives as antidiabetics | |
| TNSN06403A1 (en) | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | |
| BR0214343A (en) | 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1 | |
| ATE337316T1 (en) | IMIDAZO 1,2-AÖPYRIDINE DERIVATIVES FOR THE PROPHYLAXIS AND TREATMENT OF HERPES INFECTIONS | |
| HUP0204083A2 (en) | 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| CY1107747T1 (en) | Substituted tetraacyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors | |
| MXPA04005156A (en) | Adenosine a2a. | |
| EA200601194A1 (en) | NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR | |
| SE9903894D0 (en) | Novel compounds | |
| HUP0302521A2 (en) | Neurotrophic tacrolimus analogs, pharmaceutical compositions containing them and their use | |
| PT1206444E (en) | COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY | |
| NO20055754L (en) | Kolkisosidanaloger | |
| IT1307786B1 (en) | CERAMID ANALOGS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-TUMORAL. | |
| HUP0402062A2 (en) | Use of alkanoyl l-carnitine for the treatment of erectile dysfunction and pharmaceutical compositions containing them | |
| PE20030236A1 (en) | DERIVATIVES OF BENZIMIDAZOLE 1-ARIL-2-N, S- OR O-SUBSTITUTES, OBTAINING DRUGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES | |
| MEP59108A (en) | Memno peptides, a process for their preparation and their use | |
| HUP0302255A2 (en) | Sulfonamide derivatives, pharmaceutical compositions containing them and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: ASTELLAS PHARMA INC., JP Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP |
|
| FD9A | Lapse of provisional protection due to non-payment of fees |